An Appraisal of Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Prevention of Cardiovascular Events

References

1. ↵
   Gladding P, Webster M, Ormiston J, Olsen S, White H. Antiplatelet drug nonresponsiveness. Am Heart J 2008; 155: 591–9.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherosclerotic events. N Engl J Med 2006; 354: 1706–17.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   Fraker TD Jr, Fihn SD, Gibbons RJ. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 2007; 116: 2762–72.

   OpenUrlFREE Full Text
5. ↵
   Diener H-C, Bogousllovsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–7.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179–89.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607–21.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008; 117: 296–329.

   OpenUrlFREE Full Text
9. ↵
   Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    Bertrand ME, Rupprecht H-J, Urban P, Gershlick AH, CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102: 624–9.

    OpenUrlAbstract/FREE Full Text
11. ↵
    Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002; 288: 2411–20.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–33.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745–54.

    OpenUrlAbstract/FREE Full Text
14. ↵
    Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293): 2126–30.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500–10.

    OpenUrlAbstract/FREE Full Text
16. ↵
    Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009–19.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trial comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030–9.

    OpenUrlCrossRefPubMed
18. ↵
    Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813–8.

    OpenUrlAbstract/FREE Full Text
19. ↵
    Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297: 159–68.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667–78.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral areterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982–8.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726–30.

    OpenUrlAbstract/FREE Full Text
23. ↵
    Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347–51.

    OpenUrlAbstract/FREE Full Text
24. ↵
    Verheugt FW, Clappers N. Incidence of severe bleeding with long-term clopidogrel-aspirin combination: comparison with chronic warfarin therapy [abstract]. Circulation 2007; 116(suppl II): 441.

    OpenUrl
25. ↵
    Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004; 17: 59–67.

    OpenUrlCrossRefPubMed